Control of Glycogen Synthesis by Glucose, Glycogen, and Insulin in Cultured Human Muscle Cells
- 1School of Biochemistry and Genetics, Medical School, University of Newcastle, Newcastle upon Tyne, U.K.
- 2Target Cell Biology, Novo Nordisk, Bagsvaerd, Denmark
Abstract
A key feature of type 2 diabetes is impairment in the stimulation of glycogen synthesis in skeletal muscle by insulin. Glycogen synthesis and the activity of the enzyme glycogen synthase (GS) have been studied in human myoblasts in culture under a variety of experimental conditions. Incubation in the absence of glucose for up to 6 h caused an ∼50% decrease in glycogen content, which was associated with a small decrease in the fractional activity of GS. Subsequent reincubation with physiological concentrations of glucose led to a dramatic increase in the rate of glycogen synthesis and in the fractional activity of GS, an effect which was both time- and glucose concentration–dependent and essentially additive with the effects of insulin. This effect was seen only after glycogen depletion. Inhibitors of signaling pathways involved in the stimulation of glycogen synthesis by insulin were without significant effect on the stimulatory action of glucose. These results indicate that at least two distinct mechanisms exist to stimulate glycogen synthesis in human muscle: one acting in response to insulin and the other acting in response to glucose after glycogen depletion, such as that which results from exercise or starvation.
- DMEM, Dulbecco’s modified Eagle’s medium
- FCS, fetal calf serum
- Glu–, glucose free
- G6P, glucose-6-phosphate
- GS, glycogen synthase
- GSK, GS kinase
- PBS, phosphate-buffered saline
- PP, protein phosphatase
Footnotes
-
Address correspondence and reprint requests to Stephen J. Yeaman, School of Biochemistry and Genetics, the Medical School, University of Newcastle, Newcastle upon Tyne NE2 4HH, U.K. E-mail: s.j.yeaman{at}ncl.ac.uk.
Received for publication 7 June 2000 and accepted in revised form 20 December 2000.
R.H. has received funds from Novo Nordisk. J.G.M. is employed by and holds stock in Novo Nordisk. S.J.Y. holds stock in Xcellsyz, has received honoraria from Novo Nordisk and Glaxo Wellcome, and has received funds from Novo Nordisk and SmithKline Beecham.














